Discontinued — last reported Q4 '22
Products & Services · Research and development expense
BIIB080 — Research and development expense
Biogen BIIB080 — Research and development expense remained flat by 0.0% to $2.50M in Q4 2022 compared to the prior quarter.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2019
Last reportedQ4 2022
Rolls up toR&D
How to read this metric
An increase typically signals accelerated clinical trial activity or expanded development scope, while a decrease may indicate program completion, prioritization shifts, or cost-saving measures.
Detailed definition
This metric represents the direct costs and allocated resources dedicated to the research, clinical development, and reg...
Peer comparison
Comparable to R&D spend on specific pipeline assets at other biopharmaceutical firms, often benchmarked against clinical trial phase milestones.
Metric ID:
biib_segment_biib080_research_and_development_expenseHistorical Data
1 years
| FY'22 | |
|---|---|
| Value | $10.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's biib080 — research and development expense?
- Biogen (BIIB) reported biib080 — research and development expense of $2.50M in Q4 2022.
- What does biib080 — research and development expense mean?
- The total costs incurred to research and develop the BIIB080 drug candidate.